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Abstract
Background: Early administration of appropriate antibiotic therapy in bacteraemia patients dramatically reduces mortality.
A new method for RApid Molecular Antibiotic Susceptibility Testing (RAMAST) that can be applied directly to positive blood
cultures was developed and evaluated.
Methodology/Principal Findings: Growth curves and antibiotic susceptibility of blood culture isolates (Staphylococcus
aureus, enterococci and (facultative) aerobic Gram-negative rods) were determined by incubating diluted blood cultures
with and without antibiotics, followed by a quantitative universal 16S PCR to detect the presence or absence of growth.
Testing 114 positive blood cultures, RAMAST showed an agreement with microbroth dilution of 96.7% for Gram-negative
rods, with a minor error (false-susceptibility with a intermediate resistant strain) rate of 1.9%, a major error (false resistance)
rate of 0.8% and a very major error (false susceptibility) rate of 0.6%. Agreement for S.aureus was 97.9%, with a very major
error rate of 2.1%. Enterococcus species showed 95.0% agreement, with a major error rate of 5.0%. These agreements are
comparable with those of the Phoenix system. Starting from a positive blood culture, the test was completed within
9 hours.
Conclusions/Significance: This new rapid method for antibiotic susceptibility testing can potentially provide accurate
results for most relevant bacteria commonly isolated from positive blood cultures in less time than routine methods.
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Introduction
Invasion of bacteria in the bloodstream (bacteraemia) can result
in sepsis. Sepsis occurs in about two percent of all hospitalized
patients and in as much as 37.4% of all ICU patients and the
incidence is rising [1,2,3,4]. Mortality is high, varying from 14 to
57% [5]. Although this percentage has declined during the past
decades, due to the rising incidence of sepsis [1], the total number
of deaths through sepsis is still rising, making it the tenth leading
cause of death in the United States [6].
Early administration of appropriate antibiotics reduces mortal-
ity of sepsis dramatically [7,8,9]. Usually, empiric therapy,
consisting of one or more broad spectrum antibiotics, is started
as soon as bacteraemia is suspected. Broad spectrum antibiotics
are active against most bacteria causing bacteraemia and are often
used in combination. However, their use favors the selection of
antibiotic resistant bacteria [10]. Moreover, the more antibiotics a
patient uses, the greater the risk of drug toxicity. Additionally, the
empiric antibiotic therapy may not cover the causative micro-
organism, especially with the rising incidence of multi-drug
resistant bacteria [10]. This is the case in up to 40% of all
bacteraemia patients [9,11,12].
Rapid analysis of the antibiotic susceptibility pattern of the
causative micro-organism in bacteraemia leads to earlier targeting
of antibiotic therapy and may be lifesaving [13,14,15]. A major
drawback of the conventional blood culture systems is that once
blood cultures are positive, additional one or two overnight
incubations are required for identification of the causative micro-
organism, antibiotic susceptibility testing and targeting of
antibiotic therapy.
A new method combining culture and real-time PCR for
antibiotic susceptibility testing within 7 hours was reported by
Rolain et al. [16]. In that study, reference strains were cultured for
several hours in the presence of an antibiotic, after which growth
was measured with real-time PCR. The absence or presence of
growth indicated susceptibility or resistance to the tested antibiotic.
The aim of this study was to modify the method of Rolain et al.
in order to develop a new rapid method for RApid Molecular
Antibiotic Susceptibility Testing (RAMAST) which can be applied
directly on positive blood cultures. The study was conducted in 2
phases: (I) establishment of growth curves of bacteria harvested
from positive blood cultures using real-time PCR, to determine the
required minimal incubation time for adequate antibiotic
susceptibility testing, and (II) antibiotic susceptibility testing of
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e27689114 blood culture isolates with RAMAST, to investigate the
accuracy of RAMAST in clinical isolates.
Materials and Methods
Ethics statement
All data in this study were analyzed anonymously. Therefore,
no consent from the patients was required and the ethics
committee did not have to be approached. This is in agreement
with the code for proper use of human tissue as formulated by the
Dutch Federation of Medical Scientific Societies and the policy of
the Medical Ethics Committee of the Maastricht University
Medical Center.
Sample collection
The study was performed in the Department of Medical
Microbiology of the Maastricht University Medical Center, a 750-
bed referral hospital. Blood cultures were incubated in the Bactec
automated blood culture device (Bactec
TM 9240, BD Diagnostic
Systems, Sparks, MD, USA). Bacterial growth in the bottles was
detected through continuous monitoring of the CO2 level by the
Bactec device. Between October 2009 and July 2010, all blood
cultures that were signaled positive in the previous 24 hours and
contained Staphylococcus aureus, Enterococcus species or (facultative)
aerobe Gram-negative rods (GNRs) were included. Blood cultures
with anaerobes, Streptococcus species, coagulase-negative staphylo-
cocci (CoNS) or with growth of more than one species were
excluded from the study.
Establishment of growth curves of bacteria harvested
from positive blood cultures
Positive blood cultures (0.5 mL) were diluted 10
25 in double
concentrated Mueller Hinton II broth (212322, BBL
TM Mueller
Hinton II Broth (Cation-Adjusted), BD Diagnostic Systems). 50 ml
of this diluted blood culture was added to each well of a microtiter
plate containing 50 ml of antimicrobial solution (table 1) or sterile
demineralised water. The concentrations of the antibiotics were
based on the breakpoints for susceptibility according to the CLSI-
guideline for microbroth dilution [17]. This plate was incubated
for 0, 2, 4, 6 and 8 hours at 37uC. After incubation, the content of
the wells was transferred to sterile tubes. These were centrifuged at
160006g for 5 minutes, after which the supernatant was removed.
The remaining pellet of bacteria was suspended in demineralised
water and stored at 4uC until PCR was performed.
The real-time PCR assay used in this study was described
previously [18]. In short, the PCR-reaction mix included two
universal 16S rRNA gene primers (59-TGGAGAGTTTGAT-
CCTGGCTCAG-3 and 59-TACCGCGGCTGCTGGCAC-39),
iQ SYBR Green Supermix (Bio-Rad Laboratories BV, Veenen-
daal, the Netherlands), water and bacterial isolate. The MyiQ
Single-Color Real-Time PCR Detection System (Bio-Rad Labo-
ratories BV) was used for amplification and melt curve analysis.
The threshold was calculated automatically.
The threshold cycle value (Ct-value) was plotted against time to
establish a growth curve, in which a descending line indicates
growth.
Assessment of antibiotic susceptibility using RAMAST
After Gram-staining, 5 ml of grown blood culture was aspirated
from the blood culture bottle and the aspirate was injected in a
Serum Separator Tube (SST) (BD). This tube was centrifuged at
20006 g for 10 minutes, after which the supernatant was
discarded. Bacteria were harvested from the gel layer using a
sterile cotton swab and suspended in 0.9% saline until a 0.5
McFarland standard suspension was obtained. This suspension
was diluted in double-concentrated Mueller-Hinton II broth to an
inoculum of 5610
5 CFU/mL. This dilution was incubated in a
microtiter plate with and without antibiotics (table 1) for 6 hours at
37uC.
After incubation, the content of each well was processed for
PCR as described above, as well as a sample of diluted bacterial
suspension that was not incubated at 37uC but had instead been
stored at 4uC. To prevent inhibition of the PCR-reaction due to
high loads of bacteria, all samples were diluted 10 times in
demineralized water.
To determine antibiotic susceptibility, cut-off Ct-values were
calculated. These cut-off Ct-values were chosen from initial
growth curve experiments to obtain optimal agreement for each
drug-organism combination (data not shown). They represent the
mean of the Ct-value of the positive and negative growth control.
The positive growth control was the sample that was incubated
without antibiotics. For GNRs, the sample incubated with the
antibiotic mixture (see table 1) was used as negative growth
control. For S. aureus and Enterococcus spp. the unincubated sample
was used as negative growth control.
To calculate the cut-off Ct-values, the following formula were used:
Cut-off Ct-value 1=Ct-value positive growth control+0.56(Ct-
value negative growth control – Ct-value positive growth control)
And:
Cut-off Ct-value 2=Ct-value positive growth control+0.256(Ct-
value negative growth control – Ct-value positive growth control)
For S. aureus and enterococci, the two cut-off values were used as
follows:
– Cut-off value 1: for vancomycin and gentamicin
– Cut-off value 2: for amoxicillin, oxacillin and trimethoprim/
sulfamethoxazole
Table 1. Tested antibiotics
a and concentrations
b.
Gram-positive panel Gram-negative panel
AMX 0.25 mg/l
S AMX 8 mg/l
Eb
AMX 8 mg/l
Ec AMC 8/4 mg/l
Eb
OXA 2 mg/l
S PIP 16 mg/l
Eb, N
VAN 2 mg/l
S PIP 64 mg/l
P
VAN 4 mg/l
Ec TZP 16/4 mg/l
Eb, N
GEN 4 mg/l
S CIP 1 mg/l
Eb, P, N
STX 2/38 mg/l













aAMX, amoxicillin; OXA, oxacillin; VAN, vancomycin; GEN, gentamicin; STX,
sulfamethoxazole/trimethoprim; AMC, amoxicillin/clavulanate; PIP, piperacillin;
TZP, piperacillin/tazobactam; CIP, ciprofloxacin; CAZ, ceftazidime;
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antibiotics:
– Cut-off value 1: for amoxicillin, amoxicillin/clavulanate,
ciprofloxacin, gentamicin and trimethoprim/sulfamethoxazole
– Cut-off value 2: for piperacillin, piperacillin/tazobactam and
ceftazidim
A Ct-value higher than the cut-off Ct-value indicated
susceptibility for the antibiotic. A Ct-value lower than the cut-off
value indicated antibiotic resistance.
If a positive blood culture grew less than 1 log (a difference of
less than 3,32 Ct between the positive and negative growth
control) within 6 hours of incubation, it was excluded from
analysis, since the difference between growth and inhibition was
too small to reliably determine susceptibility or resistance.
Rapid identification of blood culture isolates
For identification, a portion of the bacterial suspension in 0.9%
saline, that was used for RAMAST, was centrifuged 160006g for
5 minutes. The supernatant was carefully removed, after which
the bacterial pellet was re-suspended in sterile demineralized
water. Along with RAMAST, after Gram-staining, rapid identi-
fication of the strains was performed using a multiplex 16S DNA
based PCR-assay described by Hansen et al [19]. By using genus-
and species-specific probes, Gram-negative bacteria were divided
into Pseudomonas aeruginosa and other Gram-negative species.
Within the Gram-positive species, probes were used to identify
Staphylococcus spp, S.aureus, Enterococcus spp and Streptococcus spp.
Routine methods for identification and antibiotic
susceptibility testing
Routine identification of GNRs was performed by the BD Phoenix
Automated Microbiology System (BD Diagnostic Systems), simulta-
neously with antibiotic susceptibility testing. For the identification of
Staphylococcus species, catalase-positive strains were tested for coagulase
and DNAse production. If both tests were positive, the strain was
identified as S. aureus. Enterococcus species were identified using bile
esculin and tellur diagnostic tablets (Product no. 40411 and 45041
resp.; Rosco Diagnostica, Taastrup, Denmark) were used, according
to manufacturer’s guidelines. If both tests were positive, the strain was
identified as Enterococcus faecalis, whereas in caseof a positive bile esculin
test but a negative tellur test, an API 20 Strep test (Biome ´rieux SA,
Marcy l’Etoile, France) was performed to further identify the strain.
For routine antibiotic susceptibility testing, the Phoenix system
was used, except or Pseudomonas aeruginosa, for which disk diffusion
according to CLSI-guidelines was performed [17].
Gold standard for antibiotic susceptibility testing
Results of antibiotic susceptibility testing with the new method
were analyzed anonymously for categorical agreement with the
results of microbroth dilution according to CLSI-guidelines, which
was used as the gold standard [17]. Errors were defined as minor,
major or very major. A major error represented a false resistant
result, and a very major error was defined as a false susceptible
result, as described previously [20]. When RAMAST showed a
susceptible result where the gold standard showed an intermediate
resistant result, this was a minor error.
Results
Phase I: Growth curves of bacteria from positive blood
cultures
First, real-time PCR was used to determine the kinetics of
growth and the optimal incubation time for Gram-positive and
Gram-negative bacteria, with and without antibiotics. Two
representative examples of growth curves of Gram-positive cocci
and Gram-negative rods established by RAMAST are shown in
Figure 1. The growth curves showed that blood culture isolates
require 6 hours of incubation before sufficient growth has
occurred for reliable antibiotic susceptibility testing with RA-
MAST.
Phase II: Susceptibility testing on positive blood cultures
with RAMAST
A total of 114 blood cultures met the inclusion criteria and were
tested for antibiotic susceptibility with the new method for RApid
Molecular Antibiotic Susceptibility Testing (RAMAST): 85 GNRs,
19 S. aureus and 10 Enterococcus spp. (table 2). Two blood cultures
had to be excluded due to insufficient growth within the 6 hours
incubation period. These were one Stenotrophomonas maltophilia
strain and one non-fermenting strain which could not be further
identified. In total, 836 antibiotic-isolate combinations were tested.
Categorical agreement of RAMAST for S. aureus was 97.9%.
Both errors in this group occurred with amoxicillin. All other
tested antibiotics showed an agreement of 100% (table 3). In the
group of Enterococcus spp, one major error was found, resulting in
an agreement of 95%.
Gram-negative rods showed an agreement of 96.7%, with a
minor error rate of 1.9%, a major error rate of 0.8% and a very
major error rate of 0.6%. The majority of errors in this group
(n=11) occurred with piperacillin and all but one of these errors
occurred in Escherichia coli strains, one error occurred with an
Enterobacter cloacae strain. All other antibiotics showed an agreement
of .93% (table 3).
In this study, the routine methods (Phoenix system and disk
diffusion) were shown to have an agreement with the gold
standard of 96.8% for S.aureus, 95.0% for Enterococcus spp. and
97.4% for GNRs.
Discussion
Here we describe a new method, RAMAST, for antibiotic
susceptibility testing directly on positive blood cultures combining
culture and real-time PCR. An overall agreement of $95% was
shown for S.aureus, Enterococcus spp. and GNRs.
For S.aureus, all antibiotics showed a 100% agreement, except
for two errors for amoxicillin. This is comparable with the results
of the Phoenix system, which also showed errors for amoxicillin in
S.aureus in this study.
In Gram-negative rods, the majority of antibiotics showed an
agreement of $93%. Only piperacillin showed a high percentage
of errors, which was also found in other methods for antibiotic
susceptibility testing [21,22,23]. All but one of these errors
occurred in amoxicillin-resistant E.coli strains, for which piper-
acillin would never be considered an appropriate treatment, so in
clinical practice, these errors would not result in an inappropriate
treatment. Nevertheless, although piperacillin would thus not be
appropriate treatment of amoxicillin resistant E. coli, RAMAST
results for piperacillin should not be reported in clinical practice.
The overall agreement of RAMAST with results of microbroth
dilution was comparable to the agreement we found for the results
of routinely used methods compared to microbroth dilution, which
in this study was 96.8% for S.aureus, 95.0% for Enterococcus spp. and
97.4% for GNRs. The results of RAMAST also meet the criteria
for selecting an antibiotic susceptibility system proposed by
Jorgensen et al [20].
RAMAST is based on a method published by Rolain et al. [16],
which combined culture and PCR for antibiotic susceptibility
Rapid Molecular Antibiotic Susceptibility Testing
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method described by Rolain et al. was not useful for rapid
antibiotic susceptibility testing on positive blood cultures. It used
bacteria from agar, thus requiring an overnight subculture of the
blood culture. Instead we used SSTs to harvest bacteria directly
from positive blood cultures, which was described previously in
other systems for antibiotic susceptibility testing [24,25,26,27,
28,29]. We found that these bacteria require 6 hours of incubation
time for reliable antibiotic susceptibility testing. Rolain et al., who
used bacteria from a fresh culture of reference strains on agar,
required only 2–4 hours of incubation time. Bacteria from positive
blood cultures may be in a stationary state because nutrients in the
blood culture broth are depleted due to the high bacterial load
[30]. This might explain why bacteria harvested directly from
positive blood cultures require more incubation time for sufficient
growth.
In contrast to Rolain et al., the PCR-assay that was used for
RAMAST did not require an extensive DNA-isolation [18].
Instead, washing the incubated diluted blood culture once was
sufficient, saving time and money. This method was also used for
the identification PCR-assay and may also prove useful for other
PCR-assays on positive blood cultures. Another advantage of this
universal 16S rRNA PCR-assay is that, in contrast to the genus- or
species specific PCR-assays used by Rolain et al., it can be used for
all bacteria, which further simplified the method.
Figure 1. Growth kinetics of P. aeruginosa and S. aureus from blood cultures with and without antibiotics. AMX, amoxicillin; OXA, oxacillin;
VAN, vancomycin; CIP, ciprofloxacin; GEN, gentamicin; AMC, amoxicillin/clavulanic acid; PIP, piperacillin; TZP, piperacillin/tazobactam; CAZ,c e f t a z i d i m .
doi:10.1371/journal.pone.0027689.g001
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RAMAST could therefore be reduced to only 9 hours, starting
from a positive blood culture.
Turnaround time of many systems for antibiotic susceptibility
testing, like broth microdilution [24,25], or automated systems like
the BD Phoenix system [26] or Vitek 2 [27,28] can also be
reduced with one day by the use of SSTs. Many of these direct
methods however showed disappointing results for Gram-positive
cocci (GPCs) [28,31] or they were not tested at all [26,32]. Our
method can be applied to the majority of clinically relevant GPCs
and (facultative) aerobic GNRs. It allows for accurate antibiotic
susceptibility testing within 9 hours, which for most strains is more
rapid than with these direct methods. This makes the test
especially useful for laboratories with extended opening hours or
24-hour laboratories.
Many studies have shown that starting early with appropriate
empirical therapy leads to a better prognosis for the patient
[7,8,9]. More rapid identification and antibiotic susceptibility
testing on positive blood cultures can reduce the time that
inadequate antibiotic therapy is administered [13,14,15,33,34]. In
this study RAMAST was combined with the rapid identification
method described by Hansen et al [19], using a multiplex PCR-
assay which required only 3 hours to perform. Alternatively, other
rapid methods for identification can be used in combination with
RAMAST; for example matrix-assisted laser desorption ionization
time-of-flight (MALDI-TOF) mass spectrometry [35] or Light-
CyclerH SeptiFast Test MGRADE (Roche).
In conclusion, our study shows that RAMAST can potentially
provide accurate results for antibiotic susceptibility testing for the
majority of clinically relevant blood culture isolates. Since the
procedure can be applied directly on positive blood cultures and
can be completed within 9 hours, results are available in less time
than other available methods for antibiotic susceptibility testing.
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